Daro Mendoza Largoza, MD
NPI 1063746014ActiveIndividual· Specialist, Research Study· New York, NY
Specialist, Research Study (MD) in New York, New York, licensed in NY, with an NPI issued in September 2009. Part D covered 412 prescriptions written in 2024, 89% of them generic. Neurocrine Biosciences, Inc. reported $108.80 in payments in 2024, mostly food and beverage.
Overview
| NPI | 1063746014 |
|---|---|
| Status | Active |
| Entity type | Individual |
| Credential | MD |
| Sole proprietor | Yes |
| NPI issued | Sep 23, 2009 |
| Last updated in NPPES | Sep 23, 2009 |
Specialties and licenses
| Taxonomy | Code | License | State |
|---|---|---|---|
| Specialist, Research Study Primary | 1744R1102X | 226955 | NY |
Exclusion screening
| List | Result | Details |
|---|---|---|
| HHS-OIG LEIE · Oct 9, 2026 | No match | Checked by NPI and by name + state |
| North Carolina Medicaid · Nov 10, 2026 | No match | — |
| New York OMIG · Nov 10, 2026 | No match | — |
| Ohio Medicaid · Nov 10, 2026 | No match | — |
| Pennsylvania Medicheck · Nov 10, 2026 | No match | — |
| Washington HCA · Nov 10, 2026 | No match | — |
Official OIG search · How matching works ·Bulk check a roster
Medicare
| Enrollment (PECOS) | Enrolled Order and Referring Only - General Practice (NY) |
|---|
Part D prescriptions in 2024
| Prescriptions (claims) | 412 · 412 30-day fills |
|---|---|
| Patients | 36 |
| Total drug cost | $19,628 |
| Generic share | 89% of claims |
Industry payments (Open Payments)
- 2024$108.80 · 1 payment from 1 company
Top paying companies in 2024
| Company | Amount | Payments |
|---|---|---|
| Neurocrine Biosciences, Inc. | $108.80 | 1 |
What the 2024 payments were for
- Food and Beverage$108.80 · 1 payment
Receiving payments does not imply wrongdoing. What Open Payments covers ·original records
Other Specialist, Research Study providers in New York
- 1043388572
- 1568333128
- 1487389367
- 1164878690
- 1932452570
- 1164303798
- 1215580089
- 1730490749
- 1235762246
- 1053611079
- 1720771801
- 1295756468